<h1>5 Toxicological and related effects of antibacterial feed additives </h1>
<h2>5.1 Introduction</h2>
<p>5.4.1 Exposure to residues</p>
<p>Spiramycin</p>
<p>Tylosin</p>
<p>Carbadox</p>
<p>Olaquindox</p>
<p>Avilamycin</p>
<p>Ardacin 5.4.2 Allergy</p>
<h2>5.5 Interactions</h2>
<h2>5.6 Summary comments</h2>
<p>References 3UPPL  288-292. 240-244.</p>
<p>WHO, Geneva. 647. 23, Noordwijkerhout. pp. 235-239. 7IENER 4IER¤RZTLICHE -ONATSSCHRIFT 135-137. 203-209. 6ETERINARY 2ECORD 367-370. 16, New Orleans. pp. 78-80. 4OXICOLOGY IN 6ITRO 141-143. 410-413.</p>
<h2>6.1 Introduction</h2>
<p>6.3.1 Disruption of microecology 6.3.2 Decreased nutrient losses</p>
<h2>6.5 Summary comments</h2>
<p>References 972-978. -ICROBIOLOGY 27-33. !GRIBIOLOGICAL 2ESEARCH 147-155. 3#" , 1997. Jordbruksstatistisk årsbok 1996. pp. 244. Statistiska centralbyrån, Örebro, Sweden. 7IERUP  - , 1996. Sverige förbjöd antibiotika i tillväxtbefrämjande syfte 1986 - vad hände med djurhälsan och hur löstes problemen? +UNGLIGA 3KOGS OCH ,ANTBRUKSAKADEMIENS 4IDSKRIFT  69-78.</p>
<h2>7 Coccidiostats</h2>
<h2>7.1 Introduction</h2>
<p>7.1.2 Prevention and chemoprophylaxis</p>
<h2>- 1930 -</h2>
<p>sulphur nitrofurazone nitrophenide nicarbazine furazolidone nitromide amprolium dinitolmide aklomide buquinolate metylbenzoquate maduramicin diclazuril semduramicin</p>
<h2>7.2 Microbiological aspects</h2>
<p>7.2.1 Parasitological aspects 7.2.2 Bacteriological aspects</p>
<h2>7.3 Toxicological aspects</h2>
<p>7.3.1 Toxicity of ionophores</p>
<p>AV MONENSIN OCH LASALOCID MG KG KROPPSVIKT (från Galitzer and W., 1984;</p>
<p>Fowler,  1995) 7.3.3 Residues</p>
<p>Ionophores</p>
<p>Other substances 7.3.4 Allergy</p>
<h2>7.4 Environmental aspects</h2>
<h2>7.5 Alternatives to coccidiostats</h2>
<p>7.5.1 Improved hygiene 7.5.3 Immunoprophylaxis 7.7.1 Introduction (ETERAKIS GALLINARUM (McDougald, 1991).</p>
<p>Pharmacokinetics</p>
<p>Toxic effects</p>
<p>References 296-298. 513. 120-125. 0OULTRY 3CIENCE 224-235. )MMUNOGENETICS 593-599. !VIAN 0ATHOLOGY 355-368. -UTATION 2ESEARCH 75-80. !RCHIV FUR 'EFLUGELKUNDE 213-220.</p>
<p>Press, London. pp. 68-104. 252. 4IJDSCHRIFT VOOR $IERGENEESKUNDE 76-82. 4IER¤RZTLICHE 5MSCHAU 3116-324. 359.</p>
<p>Edinburgh. pp. 465-494. 256-261. 1625. 499-507. /STROSKY 7EGMAN 0 ,ARES !SSEF ) 3ANTIAGO 0 %LIZONDO ' AND -ONTERO 2 , 593. -ARCH 20. 1518-1527. 670-675. 287. 232-238. !DVANCES IN 0ARASITOLOGY 219-308. 210-219. 267-270. 6ETERINARY 2ECORD 323.</p>
<h2>8.1 Introduction</h2>
<p>understanding and better risk management decisions. 8.3.1 Increased resistance</p>
<h2>P IG S</h2>
<p>A  B feed  w ater pasture</p>
<h2>S O IL</h2>
<p>w ater sew age contact and treated 3HORT TIME EFFECTS</p>
<p>Patient suffering ,ONG TERM EFFECTS 3HORT TIME EFFECTS</p>
<p>Animal suffering ,ONG TERM EFFECTS 8.3.2 Suppression of pathogens</p>
<p>N= population size, 100 000 8.3.4 Toxicological aspects</p>
<p>Target species</p>
<p>Residues</p>
<p>Occupational hazards</p>
<p>8.6.1 The benefits</p>
<p>8.6.3 The risks</p>
<p>%XPOSURE</p>
<p>4RANSMISSION EPIDEMIOLOGY</p>
<p>#ONSEQUENCES</p>
<p>8.6.4 Conclusions</p>
<p>8.6.5 Considerations for risk management decisions</p>
<p>References</p>
<p>!POTEKSBOLAGET  1996.  3VENSK ,¤KEMEDELSSTATISTIK Apoteksbolaget AB, Stockholm. pp.  pp.141-145.</p>
<p>%PIDEMIOLOGY AND )NFECTION 239-252.</p>
<p>811.</p>
<p>680-685.</p>
<p>0HARMACOTHERAPY 302-307.</p>
<p>150.</p>
<p>SUPPL  483-493.</p>
<p>1136.</p>
<p>7IERUP  - , 1996. Sverige förbjöd antibiotika i tillväxtbefrämjande syfte 1986 - vad hände med djurhälsan och hur löstes problemen? +UNGLIGA 3KOGS OCH ,ANTBRUKSAKADEMIENS 4IDSKRIFT  69-78.</p>
